2023 年第一季度报告 证券代码：688013 证券简称：天臣医疗 天臣国际医疗科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同 期增减变动幅度(%) | | | --- | --- | --- | --- | | 营业收入 | 59,472,354.75 | | 17.45 | | 归属于上市公司股东的净利润 | 11,699,630.75 | | 60.97 | | 归属于上市公司股东的扣除非经常性 | 9,007,590.21 | | 51.01 | ...

证券代码：688013 证券简称：天臣医疗 公告编号：2023-023 天臣国际医疗科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 04 日（星期四）至 05 月 10 日（星期三）16:00 前登录上证路演中心网站首页点击 "提问预征集"栏目或通过公司邮箱 tsbs@touchstone.hk 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 天臣国际医疗科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日 发布公司 2022 年年度报告，并于 2023 年 4 月 29 日发布公司 2023 年第一季度 报告，为便于广大投资者更全面深入地了解公司 2022 年度及 2023 年第一季度经 营成果、财务状况，公司计划于 2023 年 05 月 11 日 ...

Financial Performance - The company achieved a revenue of CNY 232.03 million in 2022, an increase of 8.56% compared to 2021, and a 42.05% increase compared to 2020[25]. - Net profit attributable to shareholders was CNY 43.20 million, up 4.29% year-on-year, and increased by 23.60% compared to 2020[25]. - The net profit after deducting non-recurring gains and losses was CNY 34.42 million, reflecting a 13.29% increase from the previous year[25]. - Basic earnings per share were CNY 0.54, a year-on-year increase of 3.85%[26]. - Quarterly revenue for Q4 2022 was CNY 63.76 million, with a net profit of CNY 11.40 million[28]. - The company's total assets decreased by 0.25% compared to the beginning of the reporting period, while net assets attributable to shareholders decreased by 0.73%[25]. - The company achieved operating revenue of 232.03 million yuan, an increase of 8.56% compared to the previous year[39]. - The net profit attributable to shareholders of the listed company was 43.20 million yuan, a year-on-year growth of 4.29%[39]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 34.42 million yuan, up 13.29% year-on-year[39]. - The gross margin for the medical device segment was 57.23%, a decrease of 0.24 percentage points year-on-year, with endoscopic staplers achieving a revenue of RMB 164 million, up 21.80%[105]. Research and Development - The company invested 14.98% of its revenue in R&D, an increase of 1.28 percentage points from the previous year[24]. - R&D expenses totaled 34.75 million yuan, representing an 18.69% increase compared to the previous year[42]. - The company registered 18 new product certificates during the reporting period, with 14 from its Hunan subsidiary[41]. - The company completed the R&D and registration of several new products, including electric smart staplers and automatic staplers[38]. - The company has launched several strategic R&D projects based on market and technology assessments, including the "TSRB Ligator" and "CST-T Multi-Indication Benign Disease Treatment Technology," which are now in the product registration phase[43]. - The company has adopted a "clinical insight, open competition, rapid iteration" R&D model to drive innovation and meet clinical needs effectively[52]. - The company’s R&D efforts are focused on innovative technologies that drive the transformation of traditional surgical methods, solidifying its leading position in the field[69]. - The company has filed for 25 invention patents and 34 utility model patents in the current year, contributing to a total of 1,556 patent applications[73]. - The company has completed the first phase of its equity incentive plan, aligning shareholder, company, and employee interests to promote long-term development[48]. - The company is focusing on enhancing its research and development capabilities to drive innovation and competitiveness in the market[168]. Market Expansion and Strategy - The company expanded its sales scale and market coverage, contributing to revenue growth despite market challenges[25]. - The company expanded its overseas market presence, increasing the number of cooperative countries to 31, up by 4 from 2021[41]. - The company adjusted its marketing strategy to focus on online channels in response to external market conditions[40]. - The company is actively expanding its online marketing efforts to create an integrated sales channel that combines online and offline strategies[55]. - The company is adopting a dual-driven strategy for domestic and international markets, aiming to expand its market presence and increase brand awareness through optimized marketing networks[147]. - The company is exploring potential acquisitions to further enhance its product portfolio and market presence[169]. - The company has successfully entered multiple regional bulk procurement bids in China, including in Jiangsu and Fujian provinces[86]. - The company has established long-term cooperation with B.Braun in 31 countries to promote its self-branded products[86]. Corporate Governance and Compliance - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[9]. - The company has not disclosed any special arrangements for corporate governance[8]. - The company has maintained independence from its controlling shareholders, ensuring no interference in decision-making or operations[157]. - The company strictly adheres to information disclosure obligations, ensuring transparency and protecting minority shareholders' rights[159]. - The board of directors and supervisory board operate independently, ensuring compliance with relevant laws and regulations[157]. - The company has implemented a stock incentive plan for 2022, aimed at aligning the interests of management and shareholders[162]. - The company has not provided guarantees for its controlling shareholders, maintaining financial independence[157]. - The company plans to continue its market expansion and product development strategies in the upcoming fiscal year[168]. Financial Management and Investments - The company plans to distribute a cash dividend of 2.50 RMB per 10 shares, totaling approximately 19.51 million RMB, which represents 45.17% of the net profit attributable to shareholders for the year 2022[6]. - The company does not plan to increase capital reserves or issue bonus shares for the 2022 fiscal year[6]. - The company incurred share-based payment expenses of 20.03 million yuan due to the implementation of stock incentive plans[39]. - The company reported a net cash outflow from financing activities of RMB 67.39 million, mainly due to stock repurchases during the reporting period[101]. - The company has a cash dividend policy that mandates a minimum distribution of 20% of the annual distributable profit, with higher percentages for mature companies without major capital expenditures[198]. - The company has a stable profit distribution policy that considers investor returns while ensuring sustainable development[197]. Operational Efficiency - The company is focusing on enhancing quality control and supply chain management to improve operational efficiency and reduce costs[45]. - The company is transitioning towards Industry 4.0 by investing in advanced intelligent production and testing equipment to optimize cost structures and improve product quality consistency[45]. - The company reported a 5% decrease in operational costs due to improved efficiency measures[169]. - The company confirmed a reduction in sales expenses by 9.04%, attributed to decreased market expansion costs and lower stock payment expenses[100]. - The company’s management expenses rose by 12.45% to RMB 28.98 million, driven by increased intermediary fees and intellectual property costs[100]. Challenges and Risks - The company has detailed potential risks in its operations, which can be found in the "Management Discussion and Analysis" section of the report[4]. - The company faces risks related to R&D failures, talent retention, and market competition due to the evolving landscape of the medical device industry[89][90]. - The company anticipates challenges in cost management due to the increasing concentration of the market among leading firms and the pressure from price reductions following centralized procurement policies[140].

Financial Performance - The company's operating revenue for Q3 2022 was ¥62,133,105.74, representing a year-on-year increase of 15.68%[2] - The net profit attributable to shareholders for the same period was ¥12,668,757.40, an increase of 10.31% compared to the previous year[2] - The net profit after deducting non-recurring gains and losses was ¥10,318,888.20, up 14.58% year-on-year[2] - The basic earnings per share for the period was ¥0.16, an increase of 14.29% year-on-year[2] - The diluted earnings per share was ¥0.15, a decrease of 13.33% compared to the previous year[3] - The company achieved a revenue of 168 million RMB in the first three quarters of 2022, representing a year-on-year growth of 10.07% driven by domestic bulk procurement and expansion into overseas sales regions[11] - The net profit attributable to shareholders for the first three quarters was 32 million RMB, a decrease of 12.54% compared to the previous year[11] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 27 million RMB, down 2.46% year-on-year[11] - The net profit for the first three quarters of 2022 was ¥31,792,137.04, a decrease of 12.5% from ¥36,349,565.83 in the same period of 2021[18] - The total comprehensive income for the first three quarters of 2022 was ¥31,953,731.73, compared to ¥36,463,159.96 in 2021, indicating a decline of 12.3%[19] - The total comprehensive income amounted to ¥39,112,290.17, compared to ¥36,626,017.88 in the previous year, reflecting an increase of approximately 6.8%[30] Research and Development - Research and development expenses totaled ¥8,616,102.04, accounting for 13.87% of operating revenue, a decrease of 0.79 percentage points from the previous year[3] - Research and development investment increased by 27.62% year-on-year, primarily due to higher costs associated with personnel, salaries, and materials[11] - Research and development expenses increased to ¥25,082,845.75 in 2022, compared to ¥19,654,451.01 in 2021, reflecting a growth of 27.5%[17] - The company's R&D expenses for the first three quarters of 2022 were ¥25,082,845.75, which is a 27.6% increase from ¥19,654,451.01 in the same period of 2021[29] Assets and Liabilities - The total assets at the end of the reporting period were ¥564,972,830.97, reflecting a 3.70% increase from the end of the previous year[3] - The company's total liabilities were approximately 57.08 million RMB, up from 32.71 million RMB at the end of 2021[15] - The company reported a significant increase in accounts payable, which rose to approximately 14.53 million RMB from 8.69 million RMB year-on-year[15] - The capital reserve increased to approximately 400.05 million RMB from 371.33 million RMB at the end of 2021[15] - The total assets as of September 30, 2022, amounted to ¥585,293,470.04, compared to ¥557,837,062.38 at the end of 2021, indicating a growth of 4.9%[27] - The total liabilities as of September 30, 2022, were ¥56,301,975.11, compared to ¥31,767,818.97 at the end of 2021, showing an increase of 77.5%[27] - The company's total liabilities and equity amounted to ¥564,972,830.97, an increase from ¥544,834,060.77 in the previous year[16] - The company’s retained earnings increased to ¥68,639,222.15 from ¥52,656,853.77, reflecting a growth of 30.3%[16] Cash Flow - The cash flow from operating activities for the year-to-date was ¥45,334,771.43, an increase of 8.18% year-on-year[2] - Cash flow from operating activities for the first three quarters of 2022 was ¥45,334,771.43, an increase of 8.5% from ¥41,907,766.77 in 2021[21] - The net cash flow from operating activities was ¥47,750,783.45, compared to ¥40,599,820.68 in the same period last year, representing an increase of approximately 17.3%[33] - The cash inflow from investment activities in the first three quarters of 2022 was ¥1,137,359,615.33, compared to ¥862,365,938.47 in 2021, marking a significant increase of 31.9%[21] - The net cash flow from investment activities was ¥140,388,860.64, a turnaround from a negative cash flow of -¥103,304,410.32 in the previous year[33] - The cash and cash equivalents at the end of the period were ¥224,883,005.83, significantly higher than ¥52,927,887.55 at the end of the previous period, marking an increase of 324.5%[23] - The company's cash flow from operating activities showed a positive trend, with a net increase in cash and cash equivalents of ¥151,968,383.69 compared to a decrease of -¥75,058,802.84 in the previous year[33] Shareholder Information - The company reported a total of 4,362 common shareholders at the end of the reporting period[8] - The company has implemented stock incentive plans that have impacted profit margins due to increased share-based payment expenses[11] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[29]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 106.14 million, representing a 7.03% increase compared to CNY 99.16 million in the same period last year[23]. - The net profit attributable to shareholders decreased by 23.09% to CNY 19.12 million from CNY 24.86 million year-on-year[25]. - The basic earnings per share were CNY 0.24, down 22.58% from CNY 0.31 in the previous year[24]. - The net profit excluding non-recurring gains and losses decreased by 10.65% to 16.74 million yuan[83]. - The gross profit margin improved from 58.12% to 60.76%, while operating costs only increased by 0.28% year-on-year despite a 7.03% increase in sales revenue[107]. - The company achieved a net profit attributable to shareholders of 19,123,379.64 CNY for the first half of 2022, with a basic earnings per share of 0.24 CNY/share[200]. Research and Development - The company increased its R&D investment as a percentage of operating revenue to 15.51%, up 3.63 percentage points from 11.88%[24]. - The company achieved a total R&D investment of ¥16,466,743.71, representing a 39.77% increase compared to the same period last year[64]. - R&D investment reached 16.47 million yuan, accounting for 15.51% of operating revenue, representing a 39.77% increase compared to the same period last year[86]. - The company has established a research and development model driven by clinical needs, focusing on innovation and organizational development, which is a core competitive advantage[42]. - The company has applied for 1 new invention patent and 6 utility model patents during the reporting period, with a total of 668 invention patents applied for and 297 granted[62]. - The company is expanding its R&D team and significantly increasing investment in R&D projects, including salaries, materials, and share-based payments[66]. Market Expansion and Strategy - The company is actively developing new products, including TCT (a titanium clip) and TT (a puncture device), which are currently under research[15]. - The company emphasizes the importance of compliance with regulatory standards, including CE certification and NMPA approval for its medical devices[13]. - The company expanded its international market presence, collaborating with B.Braun in 30 countries, an increase of 3 countries from 2021[84]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2023[144]. - The company is focused on expanding both domestic and international markets to boost profitability[157]. Risk Management - The company has detailed potential risks in its operations, which can be found in the management discussion and analysis section[5]. - The company faces risks related to high technical barriers and long development cycles for new products, which may impact profitability[94]. - The ongoing global pandemic and geopolitical tensions pose risks to the company's sales and market expansion efforts[103]. Corporate Governance and Compliance - The board of directors confirmed that all members attended the board meeting, ensuring the authenticity and completeness of the semi-annual report[6]. - The semi-annual report has not been audited, which may affect the perception of its financial statements[6]. - The company emphasizes high-quality R&D investment, including talent acquisition and patent layout, to continuously enhance innovation capabilities and market competitiveness[41]. - The company is actively adapting to regulatory requirements and enhancing internal control mechanisms to support long-term development[92]. Environmental and Social Responsibility - The company focuses on the research, innovation, and production of high-end surgical staplers, with minimal pollutant generation during operations, meeting discharge requirements[132]. - The company has implemented a smart control lighting system in office areas, replacing all lighting with energy-saving bulbs to reduce carbon emissions[135]. - The company has not faced any administrative penalties related to environmental issues during the reporting period, adhering to all relevant environmental laws and regulations[133]. Shareholder Relations and Profit Distribution - The company proposed a profit distribution plan for the 2022 semi-annual report, with a cash dividend of 0.20 yuan per share (including tax)[126]. - The company is committed to maintaining a dividend payout ratio of 30% of net income, ensuring shareholder returns while investing in growth[144]. - The company has a stable profit distribution policy that emphasizes reasonable returns to investors while considering sustainable development[170]. Product Development and Innovation - The company has established five major product technology platforms, including tubular anastomosis devices and linear cutting anastomosis devices, focusing on high-end surgical anastomosis device innovation[58]. - The company developed a barrier-free anastomosis technology that ensures consistent formation of anastomosis staples under various tissue conditions, addressing the "piston effect" in tubular anastomosis devices[59]. - The company’s rotating cutting technology simulates real-life cutting scenarios, improving surgical safety and success rates by ensuring reliable tissue removal[59]. - The company is in the product trial stage for several innovative medical devices, including a flexible clamp and a puncture device, aimed at improving surgical safety and effectiveness[69].

Financial Performance - The company achieved operating revenue of CNY 213.74 million in 2021, an increase of 30.85% compared to 2020[20]. - Net profit attributable to shareholders was CNY 41.42 million, up 18.52% year-on-year[23]. - The net profit after deducting non-recurring gains and losses was CNY 30.38 million, reflecting a 9.84% increase from the previous year[23]. - Total assets grew by 12.28% to CNY 544.83 million at the end of 2021 compared to the beginning of the year[24]. - The company’s total profit was reported at 66.69 million RMB, with a significant impact from share-based payment expenses amounting to 20.59 million RMB[32]. - The company reported a total revenue of 13,918 million RMB for the year, with a significant increase in user data and product usage[80]. - The company reported a revenue of $1.5 billion for the fiscal year 2021, representing a 15% increase year-over-year[191]. Research and Development - The company’s R&D expenditure accounted for 13.70% of operating revenue, an increase of 4.29 percentage points from 2020[21]. - The company invested 29.28 million RMB in R&D, a significant increase of 90.47% compared to the previous year[37]. - The company’s R&D investment increased by 90.47% year-on-year, totaling approximately ¥29.28 million, which represents 13.70% of total revenue[76][77]. - The company has developed several core technologies, including the "no-barrier anastomosis technology" and "selective cutting technology," which enhance product performance and clinical value[69][70][71]. - The company applied for 74 new patents and received 69 authorizations during the reporting period[37]. - The company holds a total of 514 patents, including 275 invention patents, covering multiple countries and regions, enhancing its competitive edge[84]. Market Expansion - The company expanded its sales regions both domestically and internationally, exceeding annual sales targets[23]. - The company expanded its market presence by collaborating with B. Braun in 27 countries, increasing coverage by over 20% compared to 2020[35]. - The company is focusing on expanding its market presence in China, which is becoming a significant source of medical technology innovation[68]. - The company plans to expand its market presence through increased direct sales, which have seen a rising proportion in total revenue[114]. - By the end of 2021, the company's products were sold in 39 countries and regions, with a significant partnership with B. Braun expanding to 27 countries, increasing from 22 in 2020[90]. Corporate Governance - The company has received a standard unqualified audit report from Zhongtianyun Accounting Firm[5]. - The company has confirmed that all board members can guarantee the authenticity, accuracy, and completeness of the annual report[7]. - The company has not indicated any special arrangements for corporate governance[7]. - The company is committed to improving governance structures to protect the rights of shareholders and enhance operational efficiency[177]. - The company has established a comprehensive information disclosure system to ensure transparency and protect minority shareholders' rights[182]. Risks and Challenges - The company has outlined potential risks in its operations, which are detailed in the management discussion and analysis section[4]. - The company faces risks related to high technical barriers and long development cycles for new products, which may lead to increased costs and delays in market entry[92]. - The ongoing global COVID-19 pandemic and geopolitical tensions pose risks to the company's sales and market expansion[103]. - The company is at risk of losing key R&D personnel, which could delay ongoing projects and impact its competitive edge[95]. - The company must continuously update its technology and products to meet the evolving demands of the surgical field, or it risks losing market relevance[96]. Product Development - The company launched new products, including the "disposable automatic insurance tubular anastomosis device" and "disposable gradient laparoscopic cutting anastomosis device," which have completed the transition to mass production[72]. - The company is actively working on projects aimed at reducing surgical trauma and complications, with a total investment of ¥29 million planned for the third-generation laparoscopic cutting anastomosis device[78]. - The company has made significant advancements in automatic safety features for its anastomosis devices, enhancing clinical safety and user experience[71]. - The company is focused on reducing complication rates associated with surgeries, aiming for improved patient outcomes through innovative product designs[80]. Financial Management - The company plans to distribute a cash dividend of 2 RMB per 10 shares, totaling approximately 15.92 million RMB, which represents 38.44% of the net profit attributable to shareholders for the year 2021[5]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated any decision-making procedures in providing guarantees[7]. - The company’s financial assets increased from 252.56 million RMB at the beginning of the period to 355.49 million RMB at the end, with a change of 102.94 million RMB[30]. - The company’s total cash and cash equivalents decreased by 40.51% to ¥75,418,385.92, mainly due to the purchase of structured deposits[135]. Shareholder Information - The company reported a total shareholding of 45,436,590 at the end of the reporting period, a decrease of 1,148,340 shares compared to the beginning of the period[188]. - The total pre-tax remuneration for the board members and senior management was 5.56 million yuan[188]. - Chairman Chen Wangyu increased his shareholding by 26,460 shares, bringing his total to 20,978,130 shares[188]. - Director Liu Wei reduced her shareholding by 1,174,800 shares, ending with 3,524,460 shares[188]. - The company held its annual general meeting and all proposed resolutions were approved without any rejections[185].

2022 年第一季度报告 证券代码：688013 证券简称：天臣医疗 天臣国际医疗科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | | | | 变动幅度(%) | | | 营业收入 | 50,634,721.73 | | 10.48 | | 归属于上市公司股东的净利润 | 7,268,188.01 | | -43.83 | | 归属于上市公司股东的扣除非 经常性损益的净利润 | 5,965 ...

Financial Performance - The company's revenue for Q3 2021 reached ¥53,710,064.08, representing a year-over-year increase of 10.30%[3] - Net profit attributable to shareholders for Q3 2021 was ¥11,484,861.94, up 17.42% compared to the same period last year[3] - The net profit attributable to shareholders for the year-to-date period was ¥36,349,565.83, showing a growth of 39.42% compared to the same period last year[3] - Total operating revenue for the first three quarters of 2021 reached ¥152,873,142.97, a 28.6% increase from ¥118,834,772.00 in the same period of 2020[15] - Net profit for the first three quarters of 2021 was ¥36,349,565.83, representing a 39.5% increase compared to ¥26,072,007.42 in the same period of 2020[16] - The company reported a total profit of ¥39,676,722.78 for the first three quarters of 2021, up from ¥30,079,904.22 in the same period of 2020[16] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥527,157,347.01, reflecting an increase of 8.64% from the end of the previous year[4] - As of September 30, 2021, the total assets of the company amounted to RMB 527,157,347.01, an increase from RMB 485,243,095.67 as of December 31, 2020, representing a growth of approximately 8.5%[12] - The company's total current assets reached RMB 451,620,494.22, up from RMB 410,287,146.44, indicating an increase of about 10.2% year-over-year[11] - The total liabilities of the company were RMB 27,930,706.80, compared to RMB 19,350,448.82 in the previous year, reflecting a rise of approximately 44.5%[13] Cash Flow - The net cash flow from operating activities for the year-to-date period increased by 40.25% to ¥41,907,766.77[4] - Cash flow from operating activities for the first three quarters of 2021 was ¥41,907,766.77, an increase from ¥29,880,847.63 in the same period of 2020[19] - The net increase in cash and cash equivalents was -$73.85 million, compared to an increase of $246.34 million in the previous period[21] - The ending balance of cash and cash equivalents was $52.93 million, down from $126.78 million at the beginning of the period[21] Research and Development - Research and development expenses for Q3 2021 totaled ¥7,873,376.33, a significant increase of 100.64% year-over-year[4] - The proportion of R&D expenses to revenue increased to 14.66%, up 6.60 percentage points from the previous year[4] - Research and development expenses for the first three quarters of 2021 were ¥19,654,451.01, a substantial increase from ¥10,112,167.41 in the same period of 2020[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,274[9] - The company reported a basic earnings per share of ¥0.14 for Q3 2021, down 12.50% from the previous year[4] - Basic and diluted earnings per share for the third quarter of 2021 were both ¥0.45, up from ¥0.43 in the same quarter of 2020[17] Equity and Reserves - The total equity attributable to shareholders rose to RMB 499,226,640.21 from RMB 465,892,646.85, an increase of approximately 7.1%[13] - The company’s capital reserve increased to RMB 363,607,806.26 from RMB 350,736,972.86, reflecting a growth of approximately 3.7%[13] - The company’s retained earnings rose to RMB 51,824,376.74 from RMB 31,474,810.91, representing an increase of about 64.7%[13] Other Financial Metrics - The weighted average return on equity decreased to 2.35%, down 4.97 percentage points year-over-year[4] - The company's cash and cash equivalents decreased to RMB 52,927,887.55 from RMB 126,781,547.45, a decline of about 58.3%[11] - Accounts receivable increased significantly to RMB 8,934,624.49 from RMB 3,236,092.55, marking a growth of approximately 176.5%[11] - The company reported a total of 9,572,341.44 in accounts payable, which increased from RMB 3,065,594.77, indicating a growth of about 212.5%[12] - Other comprehensive income after tax for the third quarter of 2021 was ¥113,594.13, compared to a loss of ¥19,243.55 in the same quarter of 2020[17] Investment Activities - Cash inflow from investment activities in the first three quarters of 2021 included ¥854,000,000.00 from recovered investments, significantly higher than ¥14,000,000.00 in the same period of 2020[19] - The company reported a total investment cash inflow of $862.37 million, with cash outflow totaling $965.67 million[21] - Net cash flow from investment activities was -$103.30 million, compared to -$111.55 million in the previous period[21] Financing Activities - Total cash inflow from financing activities was $342.79 million, while cash outflow was $32.23 million, resulting in a net cash flow of -$16.00 million[21] Leasing Standards - The company did not apply the new leasing standards starting from 2021[21]

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, achieving a total revenue of RMB 200 million, representing a growth of 25% year-over-year[13]. - The company's operating revenue for the first half of the year reached ¥99,163,078.89, a 41.37% increase compared to ¥70,142,426.22 in the same period last year[19]. - Net profit attributable to shareholders was ¥24,864,703.89, reflecting a year-on-year growth of 52.63% from ¥16,291,105.44[19]. - The net cash flow from operating activities increased by 72.22%, amounting to ¥26,643,042.38, compared to ¥15,470,566.93 in the previous year[19]. - Basic earnings per share rose to ¥0.31, a 14.81% increase from ¥0.27 in the same period last year[20]. - The company achieved a revenue of 99.16 million yuan in the first half of 2021, representing a year-on-year growth of 41.37%[58]. - The net profit attributable to shareholders reached 24.86 million yuan, a year-on-year increase of 52.63%[58]. - The total comprehensive income for the first half of 2021 was CNY 26,181,328.65, compared to CNY 16,133,570.55 in the first half of 2020, indicating a growth of 62.5%[185]. Research and Development - Research and development investments have increased by 20%, focusing on innovative surgical technologies and improving existing product lines[13]. - The company's R&D investment accounted for 11.88% of operating revenue, up from 8.82% in the previous year, indicating a focus on innovation[21]. - The company's R&D expenses increased significantly to ¥11,781,074.68 from ¥6,187,998.97, representing a growth of 90.39%[44]. - The company has developed several advanced technologies, including the no-barrier anastomosis technology, which ensures consistent formation of staples under various tissue conditions[39]. - The company has achieved significant R&D milestones, including the registration of a disposable pediatric circumcision stapler and the completion of R&D for several new products[42]. - The company is focused on developing minimally invasive surgical instruments, aligning with national policies that encourage innovation in medical device R&D[38]. - The company emphasizes a unique R&D model combining clinical procedure development with product technology, which drives innovation and efficiency[52]. Market Expansion and Strategy - The company has provided a positive outlook for the second half of 2021, projecting a revenue growth of 30% compared to the first half[13]. - The company is actively pursuing market expansion strategies, targeting an increase in its presence in Southeast Asia, with plans to enter three new countries by the end of 2021[13]. - The company has completed a strategic acquisition of a local competitor, which is anticipated to enhance its market position and increase overall market share by 5%[13]. - The company has expanded its marketing reach to 36 countries and regions, with a notable partnership with B. Braun in 26 countries, an increase of 4 countries from 2020[56][60]. - The company successfully won bids for its products in centralized procurement in Hunan and Fujian provinces, including the first inclusion of laparoscopic staplers in national procurement[59][60]. Product Development and Innovation - New product development includes the launch of the TSTmega, a disposable surgical stapler, which is expected to capture a 10% market share within the first year of its release[13]. - The company has received multiple design awards for its new products, including the Red Dot Award and iF Design Award, highlighting its commitment to innovation[27]. - The company is actively developing several innovative products, including a disposable gradient cavity mirror and an electric intelligent stapler, with total projected investments of ¥1,200 million and ¥2,690 million respectively[48]. - The company's new product "CST" received multiple international design awards, enhancing its brand recognition in the high-end medical device market[57]. Financial Management and Shareholder Commitments - The board has approved a profit distribution plan, with no plans for capital increase through retained earnings for this reporting period[13]. - The company has committed to a profit distribution mechanism to protect shareholder interests, especially for minority shareholders[121]. - The company will prioritize cash dividends, distributing at least 20% of the distributable profits in a profitable year[134]. - The company commits to ensuring that all application documents for the issuance do not contain false records, misleading statements, or significant omissions, and accepts legal responsibility for the authenticity, accuracy, and completeness of the content[123]. - The company will ensure compliance with all applicable laws and regulations during the share reduction process[109]. Risks and Challenges - The company has identified potential risks related to supply chain disruptions, which may impact production timelines and costs in the upcoming quarters[13]. - The company faces risks related to the inability to convert R&D investments into marketable products, which could adversely affect profitability[67]. - The company’s sales revenue and net profit may be negatively impacted by competitive bidding outcomes in domestic and international markets[69]. - The increase in operating costs is primarily due to the expansion of business scale and increased sales volume[73]. Environmental and Compliance - The company has established an environmental management system compliant with ISO14001:2015 standards and received certification from TUV Rheinland in February 2021[95]. - The company focuses on high-end surgical staplers, generating minimal pollutants during operations, with wastewater treated at a centralized facility[93]. - There were no administrative penalties related to environmental issues during the reporting period, and the company adhered to all relevant environmental regulations[93]. - The company has implemented measures for pollution prevention and energy conservation, aiming to create a safe and comfortable working environment[95]. Shareholder Structure and Equity - The total number of shares before the change was 80,000,000, with 77.05% being restricted shares[149]. - The largest shareholder, Chen Wangyu, held 20,934,000 shares, representing 26.22% of the total shares[156]. - The company’s total equity increased to CNY 479,985,529.72 from CNY 465,892,646.85, showing a growth of about 3.0%[172]. - The company’s total liabilities increased to CNY 24,867,046.56 from CNY 19,350,448.82, representing a rise of about 28.0%[172].

Financial Performance - The company's operating revenue for 2020 was ¥163,344,281.22, a decrease of 5.45% compared to ¥172,756,968.42 in 2019[24]. - The net profit attributable to shareholders for 2020 was ¥34,948,124.02, down 16.80% from ¥42,006,048.21 in 2019[24]. - The net profit after deducting non-recurring gains and losses was ¥27,661,445.25, a decrease of 29.05% from ¥38,987,564.97 in 2019[24]. - The basic earnings per share for 2020 were ¥0.54, a decrease of 22.86% from ¥0.70 in 2019[25]. - The gross profit margin for the main business was 58.32%, a decrease of 1.72 percentage points year-on-year, attributed to changes in product sales structure[104]. - The company achieved significant revenue growth in laparoscopic staplers, generating CNY 90.74 million, a year-on-year increase of 33.22%[106]. - The company reported a net cash flow from operating activities of CNY 42.08 million, an increase of 20.85% year-on-year[103]. Dividend Policy - The company plans to distribute a cash dividend of 2 RMB per 10 shares, totaling 16,000,000 RMB, which represents 45.78% of the net profit attributable to shareholders for the year 2020[7]. - The company will not issue new shares or stock dividends for the 2020 profit distribution plan, focusing solely on cash dividends[167]. - The company is committed to maintaining a cash dividend ratio of no less than 20% of the distributable profit in the first three years post-IPO, ensuring reasonable returns for investors[165]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 9.41% in 2020, up from 8.16% in 2019[25]. - The company achieved significant R&D milestones, including obtaining national product registration for the disposable circumcision stapler (SCC) and CE certification for three products[60]. - The company applied for 67 new patents this year, bringing the total to 1,352, with 449 patents granted[62]. - The company has established a business model centered on R&D innovation, brand building, and strict quality control, ensuring high-quality product development and market positioning[41]. - The company is focused on developing new products and technologies, including various types of surgical staplers and devices[24]. Market Trends and Opportunities - The market for surgical staplers is expected to continue growing due to increasing demand for minimally invasive surgeries and the rising prevalence of non-communicable diseases in an aging population[47]. - The global stapler market size grew from $7.364 billion in 2015 to $9.018 billion in 2019, with a compound annual growth rate (CAGR) of approximately 5%[49]. - The Chinese stapler market size increased from ¥4.827 billion in 2015 to ¥9.479 billion in 2019, achieving a CAGR of about 18%[50]. - By 2024, the Chinese stapler market is projected to reach ¥19.058 billion, with a CAGR of approximately 15% from 2019 to 2024, surpassing the global market growth rate by about 10 percentage points[51]. Risk Management - The company has outlined potential risks in its operations, which are detailed in the report[4]. - The company faces risks related to the concentration of suppliers, which could impact the stability of the supply chain if major suppliers fail to deliver[96]. - The company is at risk of losing R&D talent, which is critical for maintaining competitive advantage in product development[86]. - The COVID-19 pandemic has significantly impacted sales, particularly in overseas markets, highlighting both challenges and opportunities for growth in the medical device sector[99]. Corporate Governance - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[9]. - There are no violations of decision-making procedures regarding external guarantees[10]. - The company has outlined measures to address potential dilution of immediate returns due to stock issuance, including R&D and market expansion strategies[190]. Quality Control and Compliance - The company established a comprehensive quality management system based on ISO13485, ensuring effective monitoring and traceability of product quality throughout the entire process[75]. - The company has built a professional quality team to ensure strict quality control at all stages of product development and manufacturing[75]. - The company emphasizes product innovation and quality as core strategies to navigate challenges posed by the centralized procurement policy[97]. Strategic Initiatives - The company aims to enhance product performance and expand its market presence through continuous innovation and collaboration in the medical technology sector[55]. - The company plans to enhance its product line and support new clinical research through the construction of R&D and experimental centers, aiming to improve innovation capabilities and product quality[156]. - The implementation of the "Production Automation Technology Transformation Project" will upgrade production lines, increase automation, and expand capacity to enhance product delivery capabilities[157].